DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis
of randomised trials of antiplatelet therapy for prevention
of death, myocardial infarction, and stroke in high risk
patients. BMJ, 2002, 324:71–86. Erratum in: BMJ, 2002,
324:141.
Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic
purpura associated with clopidogrel. N Engl J
Med, 2000, 342:1773–1777.
Bentley R, Meganathan R. Biosynthesis of vitamin K
(menaquinone) in bacteria. Microbiol Rev, 1982, 46:241–280.
Blackmer AB, Oertel MD, Valgus JM. Fondaparinux and the
management of heparin-induced thrombocytopenia: The journey
continues. Ann Pharmacother, 2009, 43:1636–1646.
Blick SK, Orman JS, Wagstaff AJ, et al. Fondaparinux sodium:
A review of its use in the management of acute coronary syndromes.
Am J Cardiovasc Drugs, 2008, 8:113–125.
Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein
IIb/IIIa inhibitors in acute coronary syndromes: A
meta-analysis of all major randomised clinical trials. Lancet,
2002, 359:189–198. Erratum in: Lancet, 2002, 359:2120.
Brown MA, Stenberg LM, Persson U, Stenflo J. Identification
and purification of vitamin K-dependent proteins and peptides
with monoclonal antibodies specific for γ-carboxyglutamyl
(Gla) residues. J Biol Chem, 2000, 275:19795–19802.
Broze G Jr. Protein Z-dependent regulation of coagulation.
Thromb Haemost, 2001, 86:1–13.
Buller HR, Davidson BL, Decousus H, et al. Matisse Investigators.
Subcutaneous fondaparinux versus intravenous unfractionated
heparin in the initial treatment of pulmonary embolism. N Engl
J Med, 2003, 349:1695–1702. Erratum in: N Engl J Med, 2004,
350:423.
Butenas S, Orfeo T, Mann KG. Tissue factor in coagulation:
Which? Where? When? Arterioscler Thromb Vasc Biol, 2009,
29:1989–1996.
Butt HR, Snell AM, Osterberg AE. The use of vitamin K and bile
in treatment of hemorrhagic diathesis in cases of jaundice.
Proc Staff Meet Mayo Clin, 1938, 13:74–80.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus
warfarin in patients with atrial fibrillation. N Engl J Med, 2009,
361:1139–1151.
Daly AK, King BP. Pharmacogenetics of oral anticoagulants.
Pharmacogenetics, 2003, 13:247–252.
Dam H, Schønheyder F. The antihaemorrhagic vitamin of the
chick. Nature, 1935, 135:652–653.
Dam H, Schønheyder F, Tage-Hansen E. Studies on the mode of
action of vitamin K. Biochem J, 1936, 30:1075–1079.
Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention
Study. 2. Dipyridamole and acetylsalicylic acid in the secondary
prevention of stroke. J Neurol Sci, 1996, 143:1–13.
Diploma JR, Ritchie DM. Vitamin toxicity. Annu Rev Pharmacol
Toxicol, 1997, 17:133–148.
Edelberg JM, Christie PD, Rosenberg RD. Regulation of vascular
bed-specific prothrombotic potential. Circ Res, 2001,
89:117–124.
Esmon CT. Inflammation and the activated protein C anticoagulant
pathway. Semin Thromb Hemost, 2006, 32:49–60.
Esmon CT. The protein C pathway. Chest, 2003, 124(suppl):
26S–32S.
Feskanich D, Weber P, Willett WC, et al. Vitamin K intake and
hip fractures in women: A prospective study. Am J Clin Nutr,
1999, 69:74–79.
Fifth Organization to Assess Strategies in Acute Ischemic
Syndromes Investigators, Yusuf S, Mehta SR, et al. Comparison
of fondaparinux and enoxaparin in acute coronary syndromes.
N Engl J Med, 2006, 354:1464–1470.
Frick PG, Riedler G, Brögli H. Dose response and minimal daily
requirement for vitamin K in man. J Appl Physiol, 1967,
23:387–389.
Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous
thromboembolism: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines (8th edition).
Chest, 2008, 133(6 suppl):381S–453S.
Ghimire LV, Stein CM. Warfarin pharmacogenetics, Goodman
and Gilman Online; www.accessmedicine.com/updatesContent.
aspx?aid=1001507, accessed June 10, 2010.
Grines CL, Serruys S, O’Neill WW. Fibrinolytic therapy: Is it a
treatment of the past? Circulation, 2003, 107:2538–2542.
GUSTO III (The Global Use of Strategies to Open Occluded
Coronary Arteries) Investigators. A comparison of reteplase
with alteplase for acute myocardial infarction. N Engl J Med,
1997, 337:1118–1123.
Haroon Y, Shearer MJ, Rahim S, et al. The content of phylloquinone
(vitamin K 1
) in human milk, cows’ milk, and infant
formula foods determined by high-performance liquid chromatography.
J Nutr, 1982, 112:1105–1117.
Hawkins WB, Brinkhous KM. Prothrombin deficiency as the
cause of bleeding in bile fistula dogs. J Exp Med, 1936,
63:795–801.
Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant
therapy. Heparin: A statement for healthcare professionals
from the American Heart Association. Circulation, 2001,
103:2994–3018.
Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart
Association/American College of Cardiology Foundation
guide to warfarin therapy. Circulation, 2003, 107:1692–1711.
Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the
platelet ADP receptor targeted by antithrombotic drugs.
Nature, 2001, 409:202–207.
Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other
risk factors for excessive warfarin anticoagulation. JAMA,
1998, 279:657–662.
International Warfarin Pharmacogenetics Consortium, Klein TE,
Altman RB, et al. Estimation of the warfarin dose with clinical
and pharmacogenetic data. N Engl J Med, 2009, 360:753–764.
Jin J, Kunapuli SP. Coactivation of two different G protein-coupled
receptors is essential for ADP-induced platelet aggregation.
Proc Natl Acad Sci U S A, 1998, 95:8070–8074.
Keeley EC, Boura JA, Grines CL. Primary angioplasty versus
intravenous thrombolytic therapy for acute myocardial infarction:
A quantitative review of 23 randomised trials. Lancet,
2003, 361:13–20.
Keenan WJ, Jewett T, Glueck HI. Role of feeding and vitamin K
in hypoprothrombinemia of the newborn. Am J Dis Child,
1971, 121:271–277.
Kulman JD, Harris JE, Xie L, Davie EW. Identification of two
novel transmembrane γ-carboxyglutamic acid proteins expressed
broadly in fetal and adult tissues. Proc Natl Acad Sci U S A, 2001,
98:1370–1375.
Li T, Chang CY, Jin DY, et al. Identification of the gene for vitamin
K epoxide reductase. Nature, 2004, 427:541–544.
Lijnen HR, Collen D. Fibrinolysis and the control of hemostasis.
In: Stamatoyannopoulos G, Majerus PW, Perlmutter RM,
875
CHAPTER 30
BLOOD COAGULATION AND ANTICOAGULANT, FIBRINOLYTIC, AND ANTIPLATELET DRUGS